pGLS3-5xHRE-PHLDA3(wt)
(Plasmid
#72557)
-
PurposeHypoxia induced mutant PHLDA3. Contains the HRE from VEGF sequence (5 repeats) upstream of PHLDA3.
-
Depositing Lab
-
Depositing OrganizationUniversity of Oxford
Located in United Kingdom of Great Britain and Northern Ireland -
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 72557 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 | |
| DNA | 72557-D50 | 50 μg of DNA in Tris buffer | $495 | ||
| DNA | 72557-D100 | 100 μg of DNA in Tris buffer | $585 | ||
Backbone
-
Vector backbonepGL3-Basic
-
Backbone manufacturerPromega
-
Modifications to backbonePHLDA3 was cloned so that it replaced p53 from pGLS3-5xHRE-p53
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namePHLDA3
-
Alt namepleckstrin homology-like domain, family A, member 3
-
SpeciesH. sapiens (human)
-
Entrez GenePHLDA3 (a.k.a. TIH1)
- Promoter E1b minimal
-
Tag
/ Fusion Protein
- 5XHRE (N terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site HindIII (not destroyed)
- 3′ cloning site XbaI (not destroyed)
- 5′ sequencing primer E1B F: 5’-agatctggtaggcgtgtacgg-3’
- 3′ sequencing primer pGLS3 R: 5’-gtatcttatcatgtctgctcg-3’
- (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
5xHRE-wtp53 plasmid was used as a backbone, where p53 sequence was cut out with HindIII and XbaI enzymes.
PHLDA3 was subsequently cloned in, so PHLDA3 cloning site contains:
KpnI – 5xHRE from VEGF – BglII – E1b minimal promoter – HindIII – kozak –PHLDA3 – XbaI
DNA (Catalog # 72557-D50)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 50 μg
- Concentration 1 μg/μL
- Pricing $495 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
DNA (Catalog # 72557-D100)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 100 μg
- Concentration 1 μg/μL
- Pricing $585 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pGLS3-5xHRE-PHLDA3(wt) was a gift from Ester Hammond (Addgene plasmid # 72557 ; http://n2t.net/addgene:72557 ; RRID:Addgene_72557) -
For your References section:
Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. Leszczynska KB, Foskolou IP, Abraham AG, Anbalagan S, Tellier C, Haider S, Span PN, O'Neill EE, Buffa FM, Hammond EM. J Clin Invest. 2015 Jun;125(6):2385-98. doi: 10.1172/JCI80402. Epub 2015 May 11. 10.1172/JCI80402 PubMed 25961455